A detailed history of Caption Management, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Caption Management, LLC holds 69,200 shares of EXEL stock, worth $2.43 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
69,200
Previous 200,700 65.52%
Holding current value
$2.43 Million
Previous $4.51 Million 60.19%
% of portfolio
0.03%
Previous 0.07%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $450,816 - $566,600
20,529 Added 122.43%
37,297 $967,000
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $341,061 - $397,904
16,768 New
16,768 $376,000
Q4 2023

Feb 14, 2024

BUY
$19.25 - $24.13 $1.16 Million - $1.45 Million
60,174 Added 38.24%
217,514 $5.22 Million
Q3 2023

Nov 14, 2023

SELL
$19.04 - $22.74 $431,446 - $515,288
-22,660 Reduced 12.59%
157,340 $3.44 Million
Q2 2023

Aug 14, 2023

BUY
$18.17 - $20.48 $3.27 Million - $3.69 Million
180,000 New
180,000 $3.44 Million
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $279,004 - $324,323
18,650 Added 93.25%
38,650 $619,000
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $313,600 - $445,400
20,000 New
20,000 $314,000
Q4 2021

Feb 11, 2022

BUY
$15.84 - $21.88 $251,856 - $347,892
15,900 Added 88.33%
33,900 $620,000
Q2 2021

Aug 16, 2021

BUY
$17.95 - $25.56 $323,100 - $460,080
18,000 New
18,000 $327,000
Q1 2021

May 17, 2021

SELL
$20.53 - $25.22 $246,360 - $302,640
-12,000 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$18.39 - $24.8 $220,680 - $297,600
12,000 New
12,000 $240,000
Q2 2020

Aug 14, 2020

SELL
$16.46 - $27.42 $120,158 - $200,166
-7,300 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$14.46 - $21.8 $834,342 - $1.26 Million
-57,700 Reduced 88.77%
7,300 $126,000
Q2 2019

Aug 13, 2019

BUY
$18.93 - $24.75 $1.23 Million - $1.61 Million
65,000 New
65,000 $1.39 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.3B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.